Anti-Human IL-32 (Intermediate Domain)

Anti-Human IL-32 (Intermediate Domain)

Product No.: I-505

[product_table name="All Top" skus="I-505"]

- -
- -
Target
IL-32
Product Type
Polyclonal Antibody
Alternate Names
Interleukin-32
Applications
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Rabbit
Immunogen
PN:I-517
Product Concentration
0.5 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Rabbit Anti-Human Interleukin-32 (IL-32) recognizes an epitope in the intermediate domain of Human and Mouse IL-32. This polyclonal antibody was purified using affinity chromatography.
Antigen Distribution
IL-32 is expressed on activated lymphocytes and NK cells.
Background
IL-32 is approximately 26kD and is a pro-inflammatory cytokine that can induce cells of the immune system to secrete inflammatory cytokines including TNFα. IL-32 can also support osteoclast differentiation by regulating the MAPK/ERK pathway and the actin cytoskeleton. IL-32 can exist in at least four differentially spliced isoforms (α, β, γ and δ) with IL-32α being the shortest and most abundant of the four variants. Remarkably, it does not share sequence homology with known cytokine families and is highly expressed in immune tissues. Elevated levels of IL-32 are present in patients with coronary artery disease and endometriosis and may play a role in other autoimmune and inflammatory diseases such as rheumatoid arthritis. In a recent lung cancer study, the inhibitory effects of IL-32γ on tumor development were associated with inhibition of the STAT5 pathway which ultimately demonstrated that IL-32γ negatively regulates tumor development suggesting that IL-32γ has therapeutic potential for use in the treatment of cancer progression.

Antigen Details

PubMed
NCBI Gene Bank ID

References & Citations

1. Dahl, CA. et al. (1992) Immunol. 148:597
2. Kim, SH. et al. (2005) Immunity 22:131
3. Cagnard, N. et al. (2005) Eur. Cyto. Network 16:289
General Western Blot Protocol
- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.